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Abstract
The in vitro toxicology field seeks for reliable human relevant hepatic models for 
predicting xenobiotics metabolism and for the safety assessment of chemicals and 
developing drugs. The low availability and rapid loss of the phenotype or low bio-
transformation activity of primary hepatocytes urged the stem cell differentiation 
into hepatocyte-like cells (HLCs). Umbilical cord-derived mesenchymal stem cells 
(UC-MSC), in particular, offer a highly available cell source, with few ethical issues 
and higher genetic stability. However, the dynamic and complex microenvironment 
of liver development, including the cell-ECM and cell–cell interactions, pressure 
gradients (oxygen and nutrients) and growth factor signaling that are critical for 
the differentiation and maturation of hepatocytes, challenges the progress of in vitro 
hepatic models. Promising strategies like (i) cytokine and growth factor supple-
mentation mimicking the liver development; (ii) epigenetic modification; and (iii) 
bioengineering techniques to recreate the liver microphysiological environment are 
gaining increasing importance for the development of relevant in vitro liver models 
to address the need for higher predictivity and cost efficiency. In this context, this 
chapter reviews the existing knowledge and recent advances on the approaches for 
deriving HLCs from UC-MSC and their application for in vitro toxicology.
Keywords: human neonatal mesenchymal stem cells, umbilical cord mesenchymal 
stem cells, hepatocyte-like cells, hepatic differentiation, liver development, epigenetic 
modifiers, bioengineering, in vitro alternative models, in vitro toxicology
1. Introduction
The liver is a complex organ at the anatomical and physiological level, associated 
with numerous vital functions, including protein and urea synthesis, and regula-
tion of the energy metabolism. It is also the main organ responsible for xenobiotics 
metabolism, the reason why it is often the first to contact with their metabolic 
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products and most of the toxins, being one of the main targets of the toxicity 
caused by those drugs. Indeed, drug-induced liver injury (DILI) is responsible 
for nearly 60% of the cases of acute liver failure [1]. Despite the increased aware-
ness for DILI, its absolute frequency is not decreasing demonstrating the need for 
evaluating drugs’ hepatotoxicity and for smarter in vitro tools to increase predictiv-
ity and to represent the patients at a population level within the drug development 
process [2].
Traditional in vitro models for hepatotoxicity studies include monolayer cell 
cultures (2D) and suspensions of human hepatoma cell lines or primary hepa-
tocytes [3] (Table 1). The primary cultures of human hepatocytes present the 
most representative phenotypic and functional profile, but exhibit a short-term 
viability, with a quick loss of several cellular functions within the first days in 
culture [3], including a loss in CYP-dependent monooxygenase activities, signifi-
cant downregulation of phase I and phase II enzymes, stress-related upregulation 
of acute-phase-response enzymes and delocalization of transporter proteins. Rat 
primary hepatocytes, on the other hand, have also the disadvantage of presenting 
interspecies differences on the biotransformation of xenobiotics [4]. To overcome 
such limitations, different human hepatoma cell lines have been established. These 
can provide a high quantity of human cells and are cost-effective. However, those 
benefits are often surpassed by a number of other limitations, namely their disease-
like state, lower metabolizing capacity and incomplete biotransformation profile 
[5]. As a result, the drawbacks of the currently available models sustain the need 
for relevant human in vitro hepatotoxicity models that better resemble the in vivo 
microphysiology.
Stem cell-based hepatic models represent an important alternative to the con-
ventional hepatic in vitro systems. This chapter integrates the state of the art of 
human umbilical cord matrix (UCM-MSCs) or blood (UCB-MSCs) hepatic dif-
ferentiation and its role as an in vitro alternative model for biotransformation and 
hepatotoxicity studies.
Model Advantages Limitations Ref.
Isolated hepatocytes Obtained from whole livers or 
biopsies
Functions close to those of 
hepatocytes in vivo
Enable interspecies and 
pharmacogenomics studies
Representative of different lobular 
subpopulations
Viability: 2–4 h
No bile canaliculus
Low availability of human 
tissue
Interspecies differences
[6, 7]
Primary hepatocyte 
cultures (pHep)
Obtained from whole livers or 
biopsies
Functions close to those of 
hepatocytes in vivo
Longer viability than isolated tissue
Induction/inhibition of drug-
metabolizing enzymes
Enable interspecies and 
pharmacogenomics studies
Viability: 2–4 days
Early phenotypic changes
Altered bile canaliculi
Difficult recovery of cells and 
maintenance of function upon 
cryopreservation
Low availability of human 
tissue
Interspecies differences
[3, 7]
Hepatoma cell lines 
(HepG2, Huh7)
High proliferation activity and 
good availability
Well-characterized and abundant 
data available
Decreased drug enzyme 
activities
Genotype instability
[3, 5, 
8, 9]
Table 1. 
Advantages and limitations of traditional in vitro models for hepatotoxicity studies.
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1.1  Umbilical cord-derived mesenchymal stem cells as an alternative  
stem cell source for generating hepatocyte-like cells
Recent developments in stem cell technology have paved the way for identifying 
novel candidate sources of cells as an attempt to increase the availability of func-
tional human liver-like cells, as well as improving the reliability and the accuracy 
of drug screening in vitro [10, 11]. In fact, stem cells (SCs) are of human origin and 
possess the ability to self-replicate and differentiate into all cell types in the body. 
Regarding the liver, the differentiation strategies to derive hepatocyte-like cells 
(HLCs) from stem cells are mostly based on mimicking the development of hepato-
cytes in vivo and include the addition of soluble medium factors, the reconstruction 
of the cell-matrix and the intercellular interactions through the use of alternative 
cell culture strategies and the assessment of cell fate via genetic modifications and 
epigenetic modulation [12]. Yet, the major challenges on producing stem cell-
derived HLCs in vitro are still the immature phenotype of the HLCs [13], the lack 
of defined endpoints of hepatic differentiation and maturation [14], the absence of 
relevant positive controls [15] and defining the best stem cell source.
Several approaches have been developed for deriving HLCs from human 
embryonic stem cells (hESCs) [7, 16, 17], induced pluripotent stem cells (iPSCs) 
[7, 18–20], bipotent liver progenitor cells [21] and mesenchymal stem cells (MSCs) 
[22–42]. hESCs display various advantages for clinical applications when compared 
to immortalized cell lines and primary cell cultures, since they are genetically 
normal (diploid) and do not possess the high donor-dependent variability observed 
in primary cells [43]. The use of these cells raises, however, various ethical, techni-
cal and legal concerns [44]. Other types of SCs, like iPSCs and adult stem cells, do 
not give rise to those ethical issues. Nevertheless, there is some evidence suggesting 
that iPSC therapy has the risk of leading to tumor formation, raising safety con-
cerns that should be addressed by researchers to ensure the viability of this therapy 
[44]. iPSCs and hESCs also reveal a high risk for teratoma formation in vivo [45], 
exhibiting high genomic instability, through the accumulation of mutations [46], a 
concern that is not raised by neonatal MSCs [47]. MSCs, on the other hand, reveal 
many advantages over the other SCs, which make them suitable for toxicological 
and regenerative medicine applications. They can be isolated from non-contro-
versial sources at a relatively low cost, do not require feeder layers and high serum 
conditions, reveal a satisfactory proliferative capacity in vitro and are less immuno-
genic [23, 26, 34, 48–51]. Interestingly enough, iPSC-derived MSCs have also been 
reported as less immunogenic [52].
MSC classification is still controversial, being commonly defined as adult, fetal 
or neonatal MSCs depending on its origin. Independently of their origin, MSCs are 
characterized according to the International Society for Cellular Therapy (ISCT) 
criteria [53]. The position paper published by the ISCT states that the isolated cells 
must display: (a) plastic adherence when maintained in standard two-dimensional 
(2D) culture; (b) specific surface protein expression, typically confirmed by 
flow cytometry where a minimum of 95% of the cell population must portray the 
expression of surface markers CD105, CD73 and CD90, whereas the markers CD45, 
CD34, CD14 or CD11b, CD79α or CD19 and HLA-DR should show less than 2% 
expression among the isolated cells; and (c) tri-lineage differentiation capacity of 
the isolated cells, that is, these cells must be shown to differentiate to osteoblasts, 
adipocytes and chondroblasts using standard in vitro tissue culture-differentiating 
conditions [53].
MSCs are pluripotent stem cells that can be obtained from adult tissues like 
adipose tissue, brain, bone marrow and pancreas [54], but can also be isolated 
from neonatal tissues, like fetal-blood, amniotic sac and fluid, placenta [55] and 
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extra-embryonic tissues such as the umbilical cord (UC-MSCs) [56]. The umbili-
cal cord, in particular, represents a source of MSCs that is readily available as it is 
discarded as a medical waste after birth [57]. Herein, MSCs can be isolated from 
the blood (UCB-MSCs) or from the matrix (UCM-MSCs) through several isolation 
processes, namely by enzymatic, explants or mixed enzymatic-explant digestion 
methods [58, 59] that result in different yields [60–62].
Depending on their origin, MSCs may present variations in morphology, 
proliferation potential, growth rates and differentiation capacity as well as their 
regenerative potential. A significant advantage of the MSCs derived from neona-
tal and extra-embryonic tissues over their adult counterparts is their availability, 
extraction using non-invasive procedures, higher isolation yields and the absence 
of ethical concerns [16]. Nevertheless, other advantages have been linked to 
those cells. Several studies have reported superior cell biological properties 
such as less variability resulting from the epigenetic marks related to the donor’s 
lifestyle as well as high proliferative capacity, increased lifespan and, impor-
tantly, enhanced potency of the UC-MSCs over the other MSCs obtained from 
adult tissues (Figure 1). Indeed, in contrast to BM-MSCs, UC-MSCs maintain a 
significant expansion potential of 2.5 population doublings per week up to pas-
sage 22 (P22) keeping all MSC traits and genomic stability and without reaching 
senescence [63, 64]. Moreover, along with the adipogenic, chondrogenic and 
osteogenic lineages, UC-MSCs demonstrated differentiation ability into the 
mesodermal lineage originating from myoblasts and cardiomyocytes [65]; into 
the ectodermal lineage leading to neurons [66]; and into the endodermal lineage 
cells, giving rise to insulin-producing cells [51] and HLCs [22–42]. Besides, 
UC-MSCs can be obtained from donors with diverse pharmacogenetic profiles 
allowing for inter-individual pharmacogenomic studies and development of 
personalized therapies.
Figure 1. 
Main advantages of human umbilical cord MSCs (hUC-MSCs) over other MSC sources.
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2. Hepatocyte-like cell differentiation
2.1  Mimicking liver development by cytokines and growth factors 
supplementation
The underlying mechanisms inducing hepatocyte polarity and functional 
maturation in vitro remain largely elusive. Liver cells in vivo reside within a dynamic 
microenvironment in which biomechanical and biochemical properties of the 
extracellular matrix (ECM), dynamical cell-ECM and cell-cell interactions, pres-
sure gradients (oxygen and nutrients) and growth factor signaling are critical for 
the differentiation and maturation of hepatocytes. The relative importance of these 
various factors changes during liver development and maturation. This makes 
developing liver models enormously challenging.
Liver development has been studied using animal models, such as mouse [67], 
chicken [68], zebra fish [69] and Xenopus [70]. The knowledge of other species’ 
developmental biology contributed significantly to the progress and set up of 
protocols, which mimic the in vivo liver development, for deriving HLCs from 
human stem cells in vitro. As shown in Figure 2, the hepatogenesis process and the 
subsequent in vitro mimicking of liver development include several steps:
i. Initially, gastrulation and endoderm specification are activated by Nodal, 
bone morphogenetic protein (BMP) and Wnt signaling. Signaling by Nodal 
initiates endoderm and mesoderm formation in a concentration-dependent 
manner, in which high Nodal concentrations originate the definitive endo-
derm [71]. The endoderm induction step has been tested in vitro on ESCs 
through cell exposure to Activin A, a growth factor from the TGF-β family, 
which binds the same receptors as Nodal and therefore mimics its activity 
[72, 73].
ii. Gradients of fibroblast growth factor (FGF), Wnt, BMP and retinoic acid 
secreted from the adjacent mesoderm are responsible for patterning of endo-
derm [70, 74, 75] to generate the midgut, foregut and hindgut. Each domain 
Figure 2. 
Hepatogenesis and the respective inducing factors for in vitro differentiation of MSCs into HLCs. The addition 
of a combination of soluble factors to the culture, at defined time points, to mimic (i) endoderm commitment 
and (ii) foregut induction (EGF and FGF), followed by (iii) hepatoblast and liver bud formation (FGF, 
HGF and ITS) and finally (iv) hepatocyte differentiation and maturation (OSM, dexamethasone and 
ITS) have been shown to allow hepatic differentiation to some extent, mimicking the in vivo ontogeny. AFP, 
α-fetoprotein; ALB, albumin; BMP, bone morphogenetic protein; CK, cytokeratin; EGF, epidermal growth 
factor; FGF, fibroblast growth factor; bFGF, basic fibroblast growth factor; HGF, hepatocyte growth factor; 
HNF, hepatocyte nuclear factor; ITS, insulin-transferrin-selenium; MAPK, mitogen-activated protein kinase; 
OSM, oncostatin M.
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expresses a specific transcription factor: HHEX in the foregut, PDX1 in the 
midgut and CDX in the hindgut. Activation of the HHEX gene expression is 
essential to foregut formation and therefore its development into the liver. In 
vitro, this step is mimicked by exposing cells to growth factors such as FGF 
and EGF, once these activate the HHEX gene [74, 76].
iii. After endoderm commitment and foregut induction, the foregut receives sig-
nals from the developing heart and septum transverse mesenchyme (STM), 
which release FGF and BMP respectively, and regulate hepatic specification 
to generate hepatoblasts [71, 77]. After hepatic specification, cells start 
expressing hepatic markers, such as α-fetoprotein (AFP), albumin (ALB), 
transcription factors as CEBPA and HNF4A, and change their morphology 
from cuboidal to pseudostratified columnar epithelium, forming the liver 
bud [78]. STM and hepatic mesenchyme secrete FGF, BMP, Wnt, retinoic 
acid and hepatocyte growth factor (HGF), which promote hepatoblast 
proliferation and survival [74, 75, 79, 80]. This step is generally mimicked 
in vitro using FGF to simulate the signals sent by the developing heart and 
STM, which induce a transformation in cell disposal and morphology [77, 
79], mediating early hepatic differentiation [21]. Herein, HGF stimulates a 
mid-late hepatic phenotype and is commonly used to promote hepatoblast 
formation; however, it does not induce functional maturation [21]. FGF and 
HGF, as well as cell culture supplements like insulin-transferrin-sodium 
selenite (ITS) and nicotinamide, synergistically affect the hepatic driving 
pathway [34, 80].
iv. Finally, hepatoblasts, which are bipotent cells, can differentiate into hepato-
cytes or biliary epithelial cells. Initially, hepatoblasts express genes associated 
with both adult hepatocytes (HNF4A, ALB, CK18) and biliary epithelial cells 
(CK19), as well as fetal liver genes such as AFP [71]. Additionally, these cells 
express CK-14, DLK1, E-cadherin, EPCAM and CD133 and undergo prolifera-
tion and differentiation into hepatocytes and cholangiocytes [71]. One factor 
responsible for the induction of hepatoblast differentiation into hepatocytes 
and induction of metabolic maturation is oncostatin M (OSM), secreted by 
hematopoietic cells in the liver [81]. Indeed, several in vitro models for hepat-
ocyte differentiation use dexamethasone, HGF [22, 40, 41], OSM [25, 34, 
40] and TNF-α factors [21, 71] to induce hepatocyte maturation. Moreover, 
the use of a collagen coating [21–23, 34] improves the in vitro environment to 
promote hepatogenic differentiation by mimicking in vivo ontogeny.
The protocols, to differentiate MSC into functional hepatocytes, based on the 
in vivo liver development process can be categorized into two groups: cocktail and 
sequential. The cocktail methodology is based on one single step, whereas the 
sequential and time-dependent procedures are based on four, three, or two steps. 
Campard et al. [22] study was one of the first described studies using a three-
step-based protocol for deriving UCM-MSCs into HLCs. Herein, UCM-MSCs (also 
designated as Wharton’s jelly cells) have been isolated by an orthodox method, 
involving complex vein and arterial excisions, and the authors departed from a 
mixed, heterogeneous population of cells. Nevertheless, after the differentiation 
procedure, HLC derived from UCM-MSCs exhibited a hepatocyte-like morphol-
ogy, the presence of several hepatic markers (CK18, ALB, AFP and connexin 32), 
had glycogen storage ability, produced urea and revealed an inducible CYP3A4 
activity. Still, the absence of some hepatic markers in the differentiated UC-MSCs, 
such as HepPar1 or HNF4A, suggested that a fully mature hepatocyte phenotype 
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was not achieved. In another study, Zhao et al. [37], after hepatic differentiation of 
UC-MSC, prompted by a two-step protocol with HGF and bFGF, HLCs exhibited 
hepatocyte-like morphology and specific functions including albumin secretion, 
low-density lipoprotein uptake and urea production. In contrast, Zhang and col-
leagues [36], using a simpler cocktail induction protocol (with HGF and FGF-4), 
successfully differentiated UC-MSCs into HLCs with the same hepatic features.
Overall, those studies indicate that UC-MSCs are capable of generating 
hepatocyte-like cells with essential hepatic specific functions displaying an exciting 
potential venue toward cell-based therapeutics, human liver development studies 
and disease models for liver failure disorders. Yet, the weak characterization of the 
cells in terms of biotransformation ability has delayed their implementation for in 
vitro hepatotoxicity studies.
2.2 Epigenetic modifiers for improving HLC phenotype
Stepwise addition of factors such as EGF, FGF, HGF, nicotinamide, ITS, dexa-
methasone or OSM to the culture medium is used in the majority of the studies 
to differentiate MSCs [23, 26, 34, 35, 41]. Although the addition of these factors 
seems to lead to hepatic differentiation, a full mature hepatic cell has not yet been 
achieved. As such, the search for additional differentiation-inducing factors to 
induce a mature hepatic phenotype persists [34].
The normal function of cells is controlled by epigenetics, in which a combina-
tion of signaling pathways controls the balance between growth and differentiation. 
Therefore, besides mimicking the in vivo extracellular communication pathways by 
the use of soluble molecules, such as growth factors, cytokines, hormones and glu-
cocorticoids, one of the strategies for controlling lineage-specific gene expression 
to induce a mature hepatic phenotype is by the use of chromatin remodeling agents, 
such as epigenetic modifiers (EM) as HDAC inhibitors (HDACi), DNMT inhibitors 
(DNMTi) and microRNA (miRNA).
Epigenetic modifiers change gene expression without changing the underlying 
DNA sequence, at the chromatin level, by modulation of its architecture between 
heterochromatin (transcriptionally inactive) and euchromatin (transcriptionally 
active) [82]. Epigenetic modulation allows to silence pluripotency transcription 
factors or to activate the transcription of genes of a specific lineage contributing to 
the improvement of the HLC phenotype [34]. These mechanisms are mainly regu-
lated by DNA methylation, histone modifications and miRNA [82] as presented in 
Figure 3. Indeed, different strategies for hepatic differentiation based on epigenetic 
modification have been described so far and those include DNA methylation, 
histone modification and the use of microRNAs.
2.2.1 DNA methylation
DNA methyltransferases (DNMTs) introduce a methyl group, generally at CpG 
islands, into the DNA [82]. Decrease of DNMT1 [83] and increase of DNMT3 [84] 
expression have been shown to be associated with hepatic maturation. Hence, 
modulation of DNMTs may present a strategy for increasing liver-specific gene 
expression and consequently maintain a hepatic fate in HLCs [12]. 5-Azacytidine 
(5-AZA) is the most commonly used DNA methyltransferase inhibitor (DNMTi), 
whereas dimethyl sulfoxide (DMSO) emerges as a modulator of DNMTs [85].
The alteration of the DNA methylation status occurs as 5-AZA mimics the cytidine 
base and thus is introduced into the newly synthetized DNA strain on the S phase of the 
cell cycle [86]. On the subject of hepatocyte differentiation, Rothrock and colleagues 
[87] administered 5-AZA in utero to 20 days gestational age rat fetus resulting in a 
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quicker maturation of hepatocyte morphology, associated with higher activation of 
genes normally expressed later in liver development as TAT and ALB. In vitro, Yoshida 
et al. [25] evaluated various combinations of inducing factors, plus the addition or 
absence of 5-AZA, and verified that the 5-AZA combined with soluble factors was 
the most effective strategy for differentiating UCB-MSC that displayed a significantly 
higher ALB, CEBPA and CYP1A1/2 gene expression levels, PAS positive results and 
urea production after 21 days of differentiation. In another study, Cipriano et al. [23] 
used 5-AZA as a promoter of differentiation, in the hepatoblast-like stage of differentia-
tion, and observed a significant increase in urea production and CYP activity on HLCs.
DMSO has also been proposed as an epigenetic modifier. Although the mecha-
nism by which DMSO induces hepatic differentiation is poorly understood, Iwatani 
et al. [85] suggested that it is by upregulation of the expression of DNMT3. This 
study was performed in mouse embryoid bodies. Yoon et al. [88], on the other 
hand, used trichostatin A (TSA) or DMSO treatment for the maturation steps 
within the hepatic differentiation procedure. Herein, TSA-treated MSCs showed 
higher EROD activity (human CYP450 1A1/1A2) and ammonia conversion than 
DMSO-treated cells. Conversely, Cipriano et al. [34] showed that, in addition to the 
sequential differentiation protocol, DMSO alone (in comparison to its combination 
with TSA) induced cellular modifications on UCM-MSCs, forming epithelial-like 
binucleated cells, and stimulated a homogeneous glycogen storage and improved 
HLC biotransformation activity. The introduction of DMSO for hepatic maturation 
also resulted in a significantly improved HLC phenotype and maintenance of the 
hepatocyte features up to 2 weeks in culture [34]. Hence, more studies are necessary 
in order to determine the effectiveness of DMSO on differentiation of MSCs.
2.2.2 Histone modifications
Histone deacetylases (HDCAs) remove the acetyl group from the histones and 
modulate chromatin to regulate cell proliferation, differentiation and growth [86]. 
The most commonly used histone deacetylase inhibitors (HDACi) are TSA, sodium 
butyrate (NaBu) and valproic acid (VPA).
Figure 3. 
Control of gene transcription by epigenetic modifiers. Hypomethylated CpG islands and hyperacetylated 
histone tails at the chromatin level allow gene transcription. DNMT inhibitors (DNMTi), microRNA 
(miRNA) and HDAC inhibitors (HDACi) modulate the chromatin structure by creating an open, 
transcriptionally active euchromatin. Consequently, the enhanced accessibility of transcription complexes to 
chromatin leads to increased transcriptional activation of several epigenetically suppressed genes. 5-AZA, 
5-azacytidine; DNMT, DNA methyltransferase; HAT, histone acetyltransferase; HDAC, histone deacetylase; 
NaBu, sodium butyrate; TSA, trichostatin A; VPA, valproic acid.
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Similar to other HDACi, TSA reversibly and specifically inhibits HDAC leading 
to hyperacetylation of histones, but the exact role in hepatic differentiation and 
maturation is still unclear [88]. Exposure to TSA on primary rat hepatocytes culture 
revealed increased cell viability and albumin secretion and maintained CYP phase I 
enzymes’ capacity by controlling the expression of liver-enriched transcription fac-
tors (LETFs) and cell cycle arrest [89]. Yoon et al. [88] found that TSA-treated MSC 
presented higher activity than OSM- or DMSO-treated cells, showing an epithelial-
like shape right after treatment and higher urea production and ammonia removal 
(compared to DMSO) on day 21, as well as the expression of late hepatic markers 
such as TAT gene expression and EROD activity. Although the expression of these 
markers and functions indicate a mature HLC phenotype, these values are still 
lower than in human primary hepatocytes. Likewise, Cipriano et al. [34] tested the 
effect of 100, 500 and 1000 nM of TSA on UCM-MSC differentiation and observed 
that 1000 nM of TSA resulted in cell detachment and cell loss, whereas 100 nM did 
not present relevant morphological changes from a fibroblastic morphology to a 
more epithelial morphology during the differentiation process. Conversely, 500 nM 
of TSA resulted in higher EROD and UGT activities, as well as CK18 presence and 
epithelial morphology [34], though, as referred in the above section, TSA-treated 
cells could not surpass the results with DMSO-treated cells [34].
Several protocols for hepatic differentiation of SCs prime the cells with NaBu 
[90], in combination to Activin A [73] or bFGF and BMP4 [91], in order to induce 
the definitive endoderm prior to further maturation of HLC through, for instance, 
DMSO [92]. However, the translation of these studies to UC-MSC is still limited. To 
the best of our knowledge, only Panta et al. [26] showed that pre-treatment of UCM-
MSCs with NaBu upregulated hepatoblast and hepatocyte markers and stimulated 
mature hepatic-associated functions, such as urea production, glycogen storage and 
G6P, CEBPA, and CYP2B6 activity, compared to non-treated differentiated cells.
Finally, VPA, an antiepileptic and anticonvulsant drug, has demonstrated to 
improve stem cell hepatic differentiation when administered in low doses. An et al. 
[27] suggested that hepatic differentiation of UC-MSC is stimulated by VPA due to 
upregulation of endodermal genes such as AKT and ERK. Raut and Khana [28] also 
verified that pre-treatment of UCM-MSC with VPA enhanced the expression of 
hepatocyte-specific miRNAs typically upregulated during fetal liver development, 
such as miR-23b cluster (miR-27b-3p, miR-24-1-5p and miR-23b-3p), miR-30a-5p, 
miR-26a-5p, miR-148a-3p, miR-192-5p and miR-122-5p, which contributed to a 
more efficient hepatic transdifferentiation.
2.2.3 microRNA (miRNA)
MicroRNAs are critical regulators during the development of liver [93]. In 
humans, miR-122 is the most abundant miRNA expressed in the adult liver and is 
known to regulate hepatocyte differentiation [28, 93].
Zhou et al. [50] validated that, besides miR-122, also miR-148a, miR-424, miR-
542-5p and miR-1246 are essential for UC-MSC differentiation, given that omitting 
any of these five-miRNA combination prevented hepatic transdifferentiation. In addi-
tion, it was also demonstrated that HLCs transdifferentiated from those five microR-
NAs expressed high level of hepatic markers in only 7 days. Moreover, Khosravi et al. 
[94] studied the role of embryonic overexpressed miRNAs such as miR-106a, miR-
574-3p and miR-451 and determined that upregulation of any of these three alone 
could not induce expression of hepatic genes, such as SOX17, FOXA2, HNF4A, ALB, 
AFP and CK18. However, the concurrent ectopic overexpression of the three miRNAs 
together could induce UC-MSC differentiation into functionally mature hepatocytes 
in an easier, faster and efficient way compared to conventional techniques [94].
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In summary, these results suggest that miRNAs have a role in hepatic differentia-
tion and can rapidly and efficiently convert stem cells into functional HLC.
2.3 Bioengineering tools for hepatic differentiation
Hepatocytes need to be exposed to the native physiology of the liver and to have 
cell-cell interaction similar to the in vivo microenvironment in order to maintain 
its differentiated state [95]. Engineering tools, such as microfluidics, biomaterial 
scaffolds and bioprinting, have enabled greater control over the cellular microenvi-
ronment and, subsequently, cell response [96]. These strategies may set the ground 
for producing organs or tissues on demand to be used for animal-free drug develop-
ment and personalized medicine. Moreover, optimizing cell-cell interactions using 
different bioengineering techniques, such as 3D liver spheroids and bioprinting, 
would allow a better mimic of the in vivo physiology and thus permit to analyze 
cells’ response to drugs and other stimuli more accurately.
Different research groups reported various hepatic differentiation protocols by 
resorting to bioengineering tools. Table 2 gathers several strategies for deriving 
HLCs from different umbilical cord sections both in 2D and 3D systems.
Within the umbilical cord, investigators seem to prefer using UCM-MSCs 
over UCB-MSCs to obtain HLCs, as shown in Table 2. This may be explained as 
MSC 
source
Induction factors Controls Functional 
analysis
Hepatic 
markers
Ref.
Monolayer culture
UCB HGF, ITS, OSM, 
dexamethasone
MSC LDL uptake ALB, AFP, 
CK-18, 
CK-19, GS, 
TAT HGF, 
c-Met, 
PEPCK, CPS
[40]
EGF, bFGF, 
HGF, OSM, ITS, 
nicotinamide, 
dexamethasone
Human Hep3B 
cell line
Albumin and urea 
production, LDL 
uptake, glycogen 
storage and CYP 
activity
HNF4A, 
CYP2B6
[41]
UCM HGF, FGF-4 MSC Glycogen storage, 
LDL uptake
ALB, AFP, 
CK18
[36]
Rat-tail collagen 
type I coating; bFGF, 
HGF, nicotinamide, 
dexamethasone, 
OSM, ITS
MSC and 
freshly 
isolated liver 
cells
Glycogen storage, 
G6P and CYP3A4 
activity, urea 
production
ALB, AFP, 
CK-18, 
CK-19, 
Cnx-32, 
TAT, TDO, 
CYP3A4
[22]
Monolayer culture; hypoxia
UCM HGF, FGF-4, 
nicotinamide, 
dexamethasone, 
OSM, ITS
MSC and 
HepG2
Albumin and urea 
production, LDL 
uptake, glycogen 
storage
ALB, AFP, 
HNF4, 
CK-18, 
AAT, G6P, 
CYP3A4
[42]
Monolayer culture; overexpression of TERT
UCM Lentiviral 
transfection 
of MSC; EGF, 
HGF, ITS, OSM, 
dexamethasone
Untransfected 
MSC and 
HepG2
Urea production, 
glycogen storage
ALB, AFP, 
CK-18
[35]
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MSC 
source
Induction factors Controls Functional 
analysis
Hepatic 
markers
Ref.
Monolayer culture; epigenetic modifiers
UCM Rat-tail collagen; 
EGF, FGF-2, FGF-4, 
HGF, nicotinamide, 
dexamethasone, ITS, 
OSM, DMSO, 5-AZA
MSC, HepG2 
and human 
and rat 
primary 
hepatocytes
Albumin and 
urea production, 
glycogen storage, 
CYP and UGT 
activity
CK-18, TAT, 
AFP, ALB, 
HNF4A, 
CEBPA, 
CYP1A2, 
CYP3A4, 
OATP-C, 
MRP-2
[34]
UCB HGF, OSM, FGF-2, 
5-AZA
Not-treated 
MSC
Urea production, 
glycogen storage
ALB, 
CEBPA, 
CEBPB, 
PEPCK, 
CYP1A1, 
CYP1A2
[25]
UCM EGF, bFGF, 
HGF, OSM, ITS, 
nicotinamide, 
dexamethasone, 
NaBu
MSC not 
treated with 
NaBu, HepG2 
and mouse 
embryonic 
fibroblast cell 
line NIH3T3
Urea production, 
glycogen storage
AFP, HNF3
B, ALB, 
CK-18, G6P, 
CEBPA, 
CYP2B6
[26]
UC Rat-tail type I 
collagen coating; 
dexamethasone, 
HGF, OSM, ITS, VPA
MSC and MSC 
not treated 
with VPA
Albumin and 
urea production, 
glycogen storage, 
LDL uptake
Not studied [27]
UCM FGF-4, HGF, 
dexamethasone, 
OSM, VPA
MSC, 
differentiated 
MSC not 
treated with 
VPA and 
human adult 
liver biopsy
Albumin and 
urea production, 
glycogen storage
ALB, AFP, 
CK-18, G6P, 
TAT, AAT, 
HNF4A, 
CYP3A4, 
CYP1A1, 
miR-23b 
cluster, 
miR-26a-5p, 
miR-30a-5p, 
miR-122-5p, 
miR-148a-3p, 
miR-192-5p
[28]
3D scaffold
UCM Collagen/heparin 
coating; IGF-1, HGF, 
OSM dexamethasone,
MSC, HepG2; 
2D culture
Albumin 
production, 
glycogen storage, 
G6P and CYP2B 
activity
ALB, CK-18, 
HNF4A, 
G6P, c-Met, 
CYP2B
[29]
UC GEVAC; HGF, FGF-4, 
ITS, dexamethasone, 
OSM
MSC and 
HepG2; 2D 
culture
Albumin and urea 
production, CYP 
activity
AFP, ALB, 
G6P, AAT, 
TAT, HNF4A, 
CYP3A4
[30]
3D spheroids through cell pellet
UC HGF, bFGF, 
nicotinamide, 
dexamethasone, 
OSM, ITS
Small 
intestinal 
submucosa 
supplement 
in cell pellet; 
HepG2
Albumin and 
urea production, 
glycogen storage, 
CYP activity
ALB, 
HNF4A, 
CYP3A4
[31]
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UCM-MSCs are easier to isolate [97] and produce higher cell numbers with better 
proliferation capacities when compared to UCB-MSCs [98].
2.3.1 3D cultures of UC-MSC-derived HLCs
Animal models often fail to recapitulate human biology and are not appropriate 
to study tissue-specific mechanisms in a controlled fashion without the interfer-
ence of other tissues [99]. Thus, creating a controlled human in vitro tissue using 
3D culture techniques is a key strategy for producing reliable knowledge on drug 
toxicity and disease mechanisms [23, 29, 100]. Studies using HLCs differentiated 
from UC-MSC through 3D systems are still scarce. Nevertheless, Figure 4 illustrates 
several strategies of bioengineering for producing functional HLCs from MSCs.
Cipriano et al. [23] reported that by resorting to 3D spheroid cultures, the HLCs 
obtained from UCM-MSCs exhibited a higher glycogen stain and CYP3A4 induc-
tion when compared to the correspondent 2D cultures (Figure 5). On the other 
hand, HLCs cultured in hollow-fiber bioreactors favored diclofenac conversion and 
albumin production [23], a function mostly associated with the perivenous phe-
notype [101] that is also regulated by the blood flow-mediated shear stress [100]. 
Alternatively, Ong et al. [31] observed that MSC-derived HLCs cultured as spher-
oids in pellet culture endorsed expression of a subset of hepatic genes (CYP3A4 
and HNF4A), secreted albumin and urea, stored glycogen and showed inducible 
CYP3A4 mRNA levels. Importantly, the culture conditions allowed stable cell 
anchorage, permitted the retention of ECM molecules produced by the cells, and 
MSC 
source
Induction factors Controls Functional 
analysis
Hepatic 
markers
Ref.
3D spheroids through miniaturized hollow-fiber bioreactor and self-assembled suspension 
culture; epigenetic modifiers
UCM Rat-tail collagen 
coating; EGF, FGF-2, 
HGF, nicotinamide, 
dexamethasone, ITS, 
OSM, TSA, 5-AZA, 
DMSO
MSC and 
HepG2, 
human and 
rat primary 
hepatocytes; 
2D culture
Albumin 
and lactate 
production, 
glycogen storage, 
negative glucose 
consumption, 
CYP induction 
and UGT activity
AFP, ALB, 
CK-18, TAT, 
HHEX, 
CEBPA, 
HNF4A, 
CYP1A1, 
CYP1B1, 
CYP3A4, 
OATP-C, 
MRP-2
[23]
3D spheroids through hanging drop cell culture
UCM IGF, HGF, OSM, 
dexamethasone
DMEM-
treated MSC 
and HepG2; 
2D culture
Glycogen storage CK-18, 
CK-19, ALB
[32]
5-AZA, 5-azacytidine; AAT, α1 anti-trypsin; AFP, α-fetoprotein; ALB, albumin; C-Met, HGF receptor; CEBP, 
CCAAT enhancer-binding protein; CK, cytokeratin; CM, conditioned medium; Cnx, Connexin; CPS, carbamoyl-
phosphate synthase; CYP, cytochrome P450; DMSO, dimethyl sulfoxide; EGF, epidermal growth factor; FGF, 
fibroblast growth factor; G6P, glucose-6-phosphatase; GEVAC, gelatin-vinyl-acetate-copolymer; GS, glutamine 
synthetase; HGF, hepatocyte growth factor; HNF, hepatocyte nuclear factor; IGF, insulin-like growth factor; ITS, 
insulin-transferrin-selenium; LDL, low-density lipoprotein; miR, microRNA; MRP, multidrug resistance protein; 
MSC, mesenchymal stem cells; NaBu, sodium butyrate; OATP-C, organic anion-transporting polypeptide C; OSM, 
oncostatin M; PEPCK, phosphoenolpyruvate carboxykinase; TAT, tyrosine aminotransferase; TDO, tryptophan-2,3-
dioxygenase; TPH2, tryptophan 2,3-dioxygenase; TSA, trichostatin A; UC, umbilical cord-derived mesenchymal 
stem cells, UCB-MSC, umbilical cord blood-derived MSC; UCM-MSC, umbilical cord matrix-derived 
mesenchymal stem cells; UGT, Uridine 5′-diphosphate glucuronosyltransferase; VPA, valproic acid.
Table 2. 
Protocols for differentiation of human neonatal MSC into HLC.
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Figure 4. 
2D and 3D culture strategies for the differentiation of MSCs into HLCs and potential clinical applications. 
Several strategies such as spheroid cultures, scaffolds, bioprinting and microfluidics have shown promissory 
results and represent good tools for future studies on drug screening, disease modeling and regenerative therapies 
using fully functional HLCs.
Figure 5. 
Immunohistochemical and PAS analysis of HLCs-derived UCM-MSCs cultured in 2D cultures, in spheroids 
and in bioreactors. Representative images show the presence of the plasma protein ALB, the efflux transporter 
MRP-2, the uptake transporter protein OATP-C and the biotransformation enzymes CYP1A2 and CYP3A4. 
Cell nuclei are stained with DAPI. Scale bar: 50 μm. ALB, albumin; CYP, cytochrome P-450; HLCs, 
hepatocyte-like cells; MRP-2, multidrug resistance protein-2; OATP-C, organic anion-transporting polypeptide 
C; PAS, Periodic acid–Schiff; UCM-MSC, umbilical cord matrix mesenchymal stem cells.
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when implanted into livers of hepatectomized rats also secreted human albumin 
into the bloodstream [31].
In the region between the blood and the hepatocytes (space of Disse) lies a 
diffuse matrix composed mostly of collagen type I and fibronectin [102]. Collagen 
base scaffolds have demonstrated to improve the adult hepatocyte functions as 
they mimic the naïve hepatocyte niche [21–23, 34]. Talaei-Khozani et al. [103] and 
Khodabandeh et al. [104] compared 2D and 3D cultures of UCM-MSCs in collagen 
films and demonstrated a better hepatogenesis and increased expression of HNF4A 
on the 3D environment. Additionally, Aleahmad et al. [29] used a 3D bioprinted 
collagen and heparin scaffold and verified that heparinized 2D cultures mainly 
expressed early liver-specific markers (e.g., HNF4A, ALB, CK18 and CK19) in the 
presence of heparin, whereas the heparinized 3D cultures expressed both early and 
late liver-specific markers (e.g., G6P, CYP2B). In this study, HLCs showed a two-
fold increase in albumin production compared to monolayer cultures [29]. These 
results infer that 3D culture conditions using collagen films can prevent loss of 
hepatocyte function and improve efficiency of hepatocyte differentiation.
Scaffolds other than collagen matrixes have also been proposed to direct hepatic 
differentiation of UC-MSCs. Chitrangi et al. [30] observed that gelatin-vinyl 
acetate (GEVAC) stimulates the differentiation of UC-MSCs into hepatospheroids, 
resulting in a better maturation, higher urea production, expression of CYP3A4 and 
CYP2C9, higher percentage of albumin-positive cells and hepatic markers compared 
to 2D cultures. Hashemi et al. [33] also presented a protocol for seeding UC-MSCs 
on a poly(ε-caprolactone) (PCL) nanofiber scaffold to stimulate and then maintain 
hepatic differentiation.
2.3.2 Microfluidic technologies
The hepatic zonation corresponds to the different functions revealed by the 
hepatocytes according to their location in the hepatic lobule, which results from 
the gradient of concentration of the various nutrients and oxygen observed in 
the hepatic environment [7]. The 3D culture systems create a gradient that may 
stimulate the hepatic zonation and influence HLCs obtained. For instance, the 3D 
configuration may mimic the liver periportal environment by generating a gradi-
ent with higher oxygen, glucose and nutrients in cells closer to the capillaries in 
the culture system, for example, in the outer side of spheroids, leading to higher 
xenobiotic metabolism, urea production and glycogen synthesis [7]. The perivenous 
hepatocytes have less access to oxygen supplies and are characterized by a higher 
xenobiotic metabolism, being exposed to physiologic conditions similar to the ones 
observed around the inner cells [3, 7]. Moreover, hepatocytes are not the only cells 
present in the liver as they interact with mesenchymal cells, stellate cells, Küpffer 
cells, macrophages, and lymphocytes, and are exposed, in vivo, to a fluid perfusion 
[105]. Hence, in vitro liver function may be optimized by resorting to microfluidic 
technologies.
Microfluidic culture devices (MD) permit to control the microenvironment and 
present the ability of continued delivery of medium, drugs and soluble molecules, 
allowing the study of drug metabolism and interactions [96]. The effect of medium 
flow on inducing albumin secretion was demonstrated by Prodanov et al. [100] 
using a human primary hepatocyte 3D microfluidic system. Likewise, McCarty 
et al. [106] demonstrated the creation of spatially-controlled zonation across mul-
tiple hepatocyte metabolism levels through the application of precise concentration 
gradients of exogenous hormones (insulin and glucagon) and chemical (3-meth-
ylcholanthrene) induction agents in a microfluidic device, using monolayer rat 
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primary hepatocytes. Herein, a high concentration of insulin was directly correlated 
with a gradient in glycogen storage and urea production [106].
Studies reporting the hepatic differentiation of MSCs are still limited, but two 
studies using bone-marrow-derived MSC cultured in MDs show already a cost-
effective method for HLCs production in 3 [107] to 4 weeks [108]; however, the 
obtained HLCs were only characterized with regard to albumin and urea quantifica-
tion and showed a low metabolic performance.
3. Characterization of hepatocyte-like cells in vitro
A great amount of work has been developed over the past years for generat-
ing human stem cell-derived hepatocyte systems for in vitro toxicity testing. 
However, the definition of what is considered a differentiated HLC is still not 
unanimous and largely depends on the authors and on the purpose for which the 
cells are to be used. Currently, a wide and variable range of parameters is used 
to demonstrate the acquisition of in vivo-like hepatic features, which often leads 
to an incomplete and inconsistent cell characterization. As such, the scientific 
community would benefit from the harmonization and definition of the number 
and type of performance criteria. Indeed, Vinken and Hengstler [14] propose an 
optimal characterization aiming at benchmarking of hepatocyte-based in vitro 
systems for toxicity testing. This proposal comprises critical elements such as 
cell viability, morphology, functionality and toxicological characterization, as 
follows:
• Cell viability should be assessed using at least two methods that evaluate early 
and late key events of cytotoxicity. Moreover, a threshold of 90% viability 
should be adopted to discriminate between spontaneous cell death and cell 
death induced by toxicants.
• In terms of cellular morphology, cells must be monitored closely in order to 
confirm the maintenance of the hepatic polygonal shape and the detection of 
structural polarity markers, essential for many hepatic functions.
• Hepatocyte-specific functions, including secretion of albumin and blood 
coagulation factors, metabolism of carbohydrates and lipids, bile acid produc-
tion and transport, as well as the detoxification of endobiotics and xenobiotics 
are some of the cells functionalities to be considered. This can be performed 
through measurement of albumin and urea production, of glycogen storage 
and of biotransformation enzyme activity. Other hepatic or liver-related mark-
ers, such as HNF-1/4A and PXR, should also be evaluated.
• The toxicological characterization of hepatocyte-based in vitro systems is 
important to confirm their capacity to detect prototypical types of liver 
toxicity. This can be achieved by using hepatotoxicants capable of replicating 
human in vivo intrinsic drug-induced liver injury, namely paracetamol dose-
dependent necrosis, microvesicular steatosis induced by valproic acid and 
cholestasis induced by cyclosporine A.
However, a systematic interpretation of HLC-based in vitro systems with respect 
to their translation for the human in vivo situation remains a major challenge for 
future research.
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4. In vitro toxicological applications of HLCs
Drug attrition is a major expense in the drug development process and the use 
of advanced in vitro models will likely contribute to its reduction [109]. Detection 
of hepatotoxicity often occurs late in the drug development process and contributes 
to drug attrition, withdrawn in a post-market scheme and restriction of therapeutic 
indications [110]. Animal-based testing is currently the base for translating in vitro 
studies to clinical trials but often do not correlate with human toxicity data [99], 
mainly due to interspecies differences in drug metabolism [4]. In vitro models 
cannot directly replace animal models but may occupy a new space in which, in the 
future, animal models will become obsolete (Figure 6). In vitro models provide 
tissue-specific mechanistic insights and allow to study a high number of conditions 
with the same cells, by means of, for example, miniaturization and higher through-
put [111]. However, current in vitro application of differentiated HLCs in drug 
metabolism studies and disease modeling is still in its infancy.
Numerous studies have been published on HLCs obtained from UC-MSCs [25, 
27, 34, 35, 40] as shown in Table 2, but few were able to demonstrate cells’ biotrans-
formation capacity, as follows: Xue et al. [49] showed that HLCs from UCM-MSCs 
were capable of metabolizing midazolam through CYP3A4 activity. As mentioned 
earlier, using a three-step protocol for UCM-MSC differentiation, Campard et al. 
[22] obtained HLCs that expressed important hepatic features (ALB, G6P, TDO, 
AAT, TAT and AFP markers, glycogen accumulation and urea production) and 
exhibited CYP3A4 activity. However, the absence of markers of hepatic maturation 
such as CYP2B6 induction after exposure to phenobarbital suggested that a relevant 
phenotype was not fully achieved [22]. On the other hand, Cipriano et al. [34], in 
contrast to the results observed when comparing HepG2 and primary human hepato-
cytes (PHH), obtained a comparable expression of genes involved in drug transport, 
amino acid metabolism and proliferation of hepatocytes between UCM-MSC-
derived HLCs and PHH, indicating that HLCs are a better model for drug screening 
than low-metabolizing cell lines. In another study, using HLCs derived from UCM-
MSC in 3D spheroids culture, Cipriano et al. [23] also observed that diclofenac was 
effectively converted by CYP2C9 into its hepatotoxic metabolite, 4-OH-diclofenac, 
and was also metabolized to a lesser extent by CYP3A4 and UGTs. Furthermore, 
Figure 6. 
Potential of mature, fully functional HLCs on drug discovery and drug development. Conventional drug 
development pipelines involve preclinical in vitro and in vivo research in animal models followed by clinical 
trials on humans. In vitro toxicology models such as fully functional HLCs may shorten the way by performing 
a more similar to human toxicology screen and overcome limitations associated with poor correlation, 
interspecies differences and ethical concerns when using animal models.
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the determined IC50 felt in the range of what is found on the literature for primary 
hepatocytes, indicating that differentiated MSCs had similar dose-response char-
acteristics to mature primary hepatocytes for this hepatotoxicant. Diclofenac is one 
of the most prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) worldwide 
[112]. As such, these results permit the future use of these HLCs on drug testing and 
potential hepatotoxicity screening, which is often dependent of bioactivation.
Acetaminophen (APAP) is an over-the-counter antipyretic and analgesic drug 
widely used in several pharmacological formulations. However, in toxic doses, 
APAP causes liver injury by saturation of its main inactivation pathway and shifts to 
the transformation, by CYP2E1, CYP2D6, CYP1A2 and CYP2A6, of APAP into its 
hepatotoxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) [113]. Chitrangi 
et al. [30] used hepatospheroids derived from UC-MSCs as an in vitro model for 
studying the metabolism and toxicity of APAP. CYP3A4 and CYP1A2 were induced 
in HLCs by APAP as well as reactive oxygen species (ROS) cell damage, which lead 
to cytoskeletal disorganization, both in HLCs and primary hepatocytes.
Hepatocytes derived from SCs may also represent a platform for drug discovery 
trough disease modeling, in which in vivo cell functions and mechanisms involved 
in pathological processes on disease onset and progression may be analyzed [114]. 
There are already several liver diseases successfully modeled in vitro using iPSC-
derived hepatocytes as, for instance, familial hypercholesterolemia [115], hemo-
philia A [116], hepatitis C [117] and drug-induced hepatotoxicity [118]. One of the 
first studies to use human UC-MSCs to define a disease was Paganelli et al. [119], 
who developed an in vitro disease model to study the mechanisms underlying hepa-
titis B virus (HBV) infection by differentiating UC-MSCs into HLCs and infecting 
them with HBV. Results showed a higher susceptibility of HBV infection on HLCs 
rather than on undifferentiated MSCs. Despite low replication efficiency on HLCs, 
viral entry was as efficient as in primary hepatocytes and mimicked appropriately 
the in vivo-restricted HBV host range [119]. These similarities between the in vivo, 
in vitro gold standard and UC-MSCs lead, once again, to a promising opportunity 
for future development of in vitro models for drug discovery as human UC-MSCs 
represent a unique, human, easily available, non-transformed in vitro model.
5. Conclusion and future perspectives
This chapter provides insights into the potential use of human umbilical cord 
MSCs for obtaining a mature HLC phenotype suitable for in vitro toxicological 
studies. As primary hepatocytes present limited capacity to expand ex vivo, the pos-
sibility of obtaining comparable hepatocyte-like cells from MSCs may alleviate the 
low cell availability of human primary hepatocytes. Moreover, the use of MSCs in 
a physiologically relevant microenvironment that generates fully functional HLCs 
would allow an integrated approach to study xenobiotics biotransformation and 
mechanisms of action (MoA) or toxicity (MoT).
The differentiation process of MSCs into HLCs and their potential toxicology 
application are still in their infancy and, in the following years, there are still major 
challenges to resolve before their relevant application. Firstly, improvement of the effi-
ciency of hepatic induction in vitro and in vivo still requires further investigation on the 
hepatic transdifferentiation mechanisms of UC-MSCs. Secondly, the differentiation 
process is long and the generation and maintenance of high numbers of HLCs are still 
difficult to achieve. The definition of the most relevant endpoints of hepatic differen-
tiation and maturation is of extreme importance. Thirdly, the use of relevant positive 
controls such as human primary hepatocytes is essential for benchmarking HLCs and 
its absence represents a major issue in evaluating most of the published studies.
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As such, further studies will be required to allow the use of HLCs derived from 
UC-MSCs in the drug development process, but the strategies described in this 
chapter represent the first step toward the establishment of a relevant human 
in vitro hepatic model for toxicological studies. Exploring the full potential of 
UC-MSCs by the introduction of mechanistic models for toxicity testing, including 
in vitro disease models and hepatotoxicity models, at the pipeline of drug discovery 
and development will significantly reduce compound attrition rate and progres-
sively substitute current animal models by selecting safer and more efficacious lead 
molecules.
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Appendices and Nomenclature
2D two-dimensional
3D three-dimensional
5-AZA 5-azacytidine
AAT α1 anti-trypsin
AFP α-fetoprotein
ALB albumin
BMP bone morphogenetic protein
CEBP CCAAT enhancer-binding protein
CK cytokeratin
CYP cytochrome P450
DILI drug-induced liver injury
DMSO dimethyl sulfoxide
DNMTi DNA methyltransferase inhibitors
EGF epidermal growth factor
EROD 7-ethoxyresorufin-O-deethylase
FGF fibroblast growth factor
G6P glucose-6-phosphatase
GS glutamine synthetase
HDACi histone deacetylase inhibitors
hESCs human embryonic stem cells
HGF hepatocyte growth factor
HLC hepatocyte-like cell
HLCs hepatocyte-like cells
HNF hepatocyte nuclear factor
hnMSC human neonatal mesenchymal stem cell
hnMSCs human neonatal mesenchymal stem cells
hUCB-MSCs human umbilical cord blood mesenchymal stem cells
hUCM-MSCs human umbilical cord matrix mesenchymal stem cells
hUC-MSC human umbilical cord-derived mesenchymal stem cell
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IGF insulin-like growth factor
iPSCs induced pluripotent stem cells
ITS insulin-transferrin-selenium
LDL low-density lipoprotein
MD microfluidic culture device
MiR microRNA
MSC mesenchymal stem cells
NaBu sodium butyrate
OSM oncostatin M
PAS periodic acid Schiff ’s
SCs stem cells
TAT tyrosine aminotransferase
TDO tryptophan-2,3-dioxygenase
TSA trichostatin A
UGT uridine 5′-diphosphate glucuronosyltransferase
VPA valproic acid
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